Literature DB >> 25600059

Alterations in drug disposition in older adults.

Emily Reeve1, Michael D Wiese, Arduino A Mangoni.   

Abstract

INTRODUCTION: The worldwide population is aging, and several age-associated physiological and pathophysiological changes can affect drug disposition. This is particularly important in view of the extensive medication prescribing and exposure in older adults. AREAS COVERED: Using a framework of the four primary pharmacokinetic processes (Absorption, Distribution, Metabolism and Elimination), this review discusses the current evidence of the pharmacokinetic changes that occur with aging, particularly 'healthy aging,' focusing on developments in this field over the last 10 years. EXPERT OPINION: A substantial amount of work has been conducted to address whether advancing age significantly affects drug disposition in humans. Despite significant advances in the field, particularly regarding drug metabolism and elimination, a number of issues remain unsolved. In particular, lack of inclusion of older adults with multimorbidity and those aged > 80 and minimal evidence in relation to new drugs limits the applicability of findings to current clinical practice.

Entities:  

Keywords:  absorption; aging; distribution; elimination; metabolism; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25600059     DOI: 10.1517/17425255.2015.1004310

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  24 in total

1.  Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.

Authors:  Izna Ali; Daniel Guidone; Joseph A Nicolazzo; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 2.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

Review 3.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

4.  Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research.

Authors:  Mohammed Saji Salahudeen; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

5.  The Ethics of Deprescribing in Older Adults.

Authors:  Emily Reeve; Petra Denig; Sarah N Hilmer; Ruud Ter Meulen
Journal:  J Bioeth Inq       Date:  2016-07-14       Impact factor: 1.352

Review 6.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

Review 7.  Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Eur Geriatr Med       Date:  2021-01-08       Impact factor: 1.710

8.  Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia.

Authors:  Aymen Ali Al-Qurain; Lemlem G Gebremichael; Mohammed S Khan; Desmond B Williams; Lorraine Mackenzie; Craig Phillips; Patrick Russell; Michael S Roberts; Michael D Wiese
Journal:  Int J Clin Pharm       Date:  2020-11-18

9.  Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

10.  Clinical practice guidelines for older people with multimorbidity and life-limiting illness: what are the implications for deprescribing?

Authors:  Daniel Okeowo; Alastair Patterson; Cynthia Boyd; Emily Reeve; Danijela Gnjidic; Adam Todd
Journal:  Ther Adv Drug Saf       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.